Trials that tried to demonstrate the efficacy of an anti-IL17c monoclonal antibody were stopped for futility; however, this therapeutic target could be reconsidered following the stratification of patients and after having outlined, where possible, a more careful molecular profile of some AD phenotypes, starting, for example, with the non-responding patients to target therapies that are currently available. This evidence concerns the gene IL17C and Alzheimer disease.